Neuroscience & Research
From serotonin receptors to clinical breakthroughs — the rigorous research that is transforming psychiatry.
Psychedelics, also known as hallucinogens, are a class of substances that produce profound changes in consciousness, perception, and thought. They are characterized by their ability to induce vivid and often intense experiences of altered reality — including hallucinations, increased feelings of empathy and interconnectedness, and mystical or spiritual insights. Psychedelic drugs have been used for thousands of years by indigenous cultures for spiritual and medicinal purposes, and have more recently become the subject of rigorous scientific research and clinical trials.
While the legality of psychedelics remains a complex and evolving issue globally, the scientific and spiritual communities are increasingly exploring their therapeutic and historical significance. This page is dedicated to the science — the chemistry, the neurobiology, the clinical data, and the researchers pushing the field forward.
"The results so far have been remarkable. We are not talking about marginal improvements — we are talking about profound, lasting changes in people who had failed every other treatment available."
Psychedelics temporarily quiet the Default Mode Network — allowing new neural pathways to form and old patterns to dissolve.
Chapter One
Psychedelics are a unique class of psychoactive drugs that produce profound changes in consciousness, perception, and mood. Despite their diverse chemical structures, psychedelics primarily exert their effects by interacting with the serotonin 2A receptor (5-HT2A) in the brain. They modulate the Default Mode Network (DMN) — a network of brain regions responsible for self-referential processing, introspection, and mind-wandering. By decreasing DMN activity, psychedelics produce a state of heightened openness to new ideas, emotions, and experiences.
The pharmacological effects also involve changes in cortical connectivity — particularly an increase in cross-network communication between the DMN and other brain regions. Studies using functional MRI have shown that psychedelics enhance the synchrony of brain activity between the DMN and the task-positive network (TPN), which becomes active during attention-demanding tasks. This heightened connectivity is thought to underlie the "ego dissolution" and blurring of boundaries between self and the external world commonly reported during psychedelic experiences.
Despite the recent resurgence of interest, the precise mechanisms by which these drugs exert their effects remain an active area of investigation. New research in neuroscience and psychology is shedding light on the neural correlates of psychedelic experiences and their therapeutic applications — including treatment of anxiety, depression, PTSD, and addiction.
Chapter Two
Psychedelics have been studied extensively for their potential therapeutic effects on mental health. These substances work by activating the serotonin 2A receptor, leading to altered perception and a state of mind often characterized by a sense of unity and interconnectedness. The psychedelic experience is frequently described as "mystical" or "transcendent," and has been linked to increased feelings of well-being and decreased symptoms of depression and anxiety.
Research has shown that psychedelics can have lasting positive impacts on mental health. A study published in the Journal of Psychopharmacology found that a single dose of psilocybin led to significant and lasting reductions in symptoms of depression and anxiety in patients with life-threatening cancer. A study in the Journal of Nervous and Mental Disease found that psilocybin-assisted therapy led to significant reductions in treatment-resistant depression.
Psychedelics have also been studied for their potential to enhance cognitive function, creativity, and problem-solving — likely due to the way these substances disrupt default mode network activity and allow for increased connectivity between different brain regions.
"Participants rate their psilocybin sessions among the most meaningful experiences of their lives — comparable to the birth of a child or the death of a parent. And the therapeutic effects last." — Johns Hopkins Research Team
Chapter Three
Psychedelic drugs come in a variety of forms — natural compounds found in plants, synthetic derivatives, and chemically modified versions of naturally occurring substances. Each has different effects, dosages, durations, and risk profiles.
Psilocybin
Found in "magic mushrooms." First isolated by Albert Hofmann in 1958. Produces visual and auditory hallucinations, altered time perception, and intense emotional experiences. Currently the most studied psychedelic in clinical settings.
DMT
Dimethyltryptamine — found in the ayahuasca vine and Chacruna plant. First synthesized in 1931. Known for inducing intense, short-lived hallucinations. Considered one of the most powerful psychedelics in existence.
Mescaline
Found in the peyote and San Pedro cacti. Used for centuries by indigenous cultures in Mexico and the southwestern United States for spiritual and medicinal purposes. Known for intense visual hallucinations lasting several hours.
Iboga
From the root bark of the iboga plant, native to West Africa. Used for centuries by the Bwiti religion in Gabon. Known for intense visual and auditory hallucinations, heightened awareness, and increased spiritual insight.
Ayahuasca
A brew made from the ayahuasca vine and chacruna leaves. Used traditionally in the Amazon basin for spiritual and medicinal purposes. Effects can last 2–6 hours and are often described as profound and transformative.
Synthetic psychedelics are manufactured in a laboratory rather than found in nature. The most well-known is LSD (Lysergic acid diethylamide), first synthesized in 1938 by Swiss chemist Albert Hofmann, who is widely recognized for this discovery. LSD became known for producing profound changes in perception and thought, and sparked the first wave of clinical research in the 1950s and 60s.
Among the most important figures in the history of synthetic psychedelics are Alexander "Sasha" Shulgin and his wife Ann Shulgin. Sasha synthesized over 200 new psychedelic compounds, many of which he tested on himself and documented alongside Ann. Together they are also known for their research into the therapeutic potential of these substances and for advocating their responsible use.
Chapter Four
Several institutions have emerged as leaders in the current wave of psychedelic research — now often called the Psychedelic Renaissance.
The Multidisciplinary Association for Psychedelic Studies (MAPS) is a nonprofit focused on developing medical, legal, and cultural contexts for the safe use of psychedelics. Since 1986, MAPS has conducted clinical trials exploring the therapeutic potential of MDMA, psilocybin, and ayahuasca — with its primary initiative being MDMA-assisted psychotherapy for PTSD in military veterans, sexual assault survivors, and other groups.
The Johns Hopkins Center for Psychedelic and Consciousness Research, established in 2019, is dedicated to rigorous scientific study of psychedelics for conditions including depression, anxiety, and addiction. Among its most significant research is ongoing study of the effects of psilocybin on patients with treatment-resistant depression.
Imperial College London has explored the potential of psychedelics in treating depression, anxiety, and addiction. UCLA launched its Psychedelic Science Center to support research into the effects of these substances on brain function and mental health. The work being done at all of these institutions is opening new avenues for treating a range of mental health conditions and deepening our scientific understanding of consciousness itself.
"We have gathered all the details. We have the roadmap. The next great frontier is not the edge of space, but the interior landscape of the conscious self."
Continue Exploring